American Academy

NJIT's Undergrad Forensics Program Awarded National Accreditation, a First in NJ

Retrieved on: 
Wednesday, March 20, 2024
Growth, Environmental science, Forensic science, Education, Knowledge, Accreditation, Research, NJIT, American Academy, Faculty, Student, DOJ, Council, Nursing

Newark, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- NJIT’s undergraduate forensic science program has been awarded full accreditation from the Forensic Science Education Programs Accreditation Commission (FEPAC) of the American Academy of Forensic Sciences — a distinction held by less than 35 undergraduate forensics programs nationwide.

Key Points: 
  • Newark, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- NJIT’s undergraduate forensic science program has been awarded full accreditation from the Forensic Science Education Programs Accreditation Commission (FEPAC) of the American Academy of Forensic Sciences — a distinction held by less than 35 undergraduate forensics programs nationwide.
  • FEPAC is regarded as the main accrediting body for college-level forensic science education in the U.S., recognized by the Council for Higher Education Accreditation.
  • “Graduating from an accredited program also makes students more competitive in the job market,” said Fisher.
  • NJIT’s forensic program’s newest concentration in the rapidly growing field of digital forensics is expected to be awarded FEPAC accreditation next year when it becomes eligible.

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Retrieved on: 
Monday, March 18, 2024
Research, Adverum Biotechnologies, Vasculitis, Three Months, Macula, Chorioretinitis, Inflammation, Patient, Episcleritis, American Academy, Anti-VEGF, LUNA, Intraocular pressure, Investment, Clinical trial, Injection, Safety, Drug development, Paratriathlon, AMD, AAO, OPTIC, Retinitis, CST, Vascular occlusion, Annual general meeting, VEGF, Pharmaceutical industry

REDWOOD CITY, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2023. The company also provided recent pipeline highlights and corporate updates.

Key Points: 
  • The company also provided recent pipeline highlights and corporate updates.
  • 85% and 68% of patients at the 2E11 and 6E10 doses, respectively, received no supplemental injections through 26 weeks.
  • Stock-based compensation expense included in research and development expenses was $1.0 million for the fourth quarter of 2023.
  • Stock-based compensation expense included in general and administrative expenses was $3.1 million for the fourth quarter of 2023.

Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress

Retrieved on: 
Monday, March 18, 2024
Research, TNF, AON, Dexamethasone, Congress, International, International Financial Reporting Standards, Telecanthus, Inflammation, DME, Patient, SNP, NDA, American Academy, G&A, POC, Business analyst, IND, Abstract, DED, Bank statement, Genotype, Investment, Retina, Diabetic retinopathy, OCS, Safety, CHF, Pain, Stage 2, Pharmaceutical industry

Riad Sherif M.D., Chief Executive Officer of Oculis: “2023 was a remarkable milestone-rich year for Oculis.

Key Points: 
  • Riad Sherif M.D., Chief Executive Officer of Oculis: “2023 was a remarkable milestone-rich year for Oculis.
  • These non-IFRS financial measures exclude the impact of items that the Company’s management believes affect comparability or underlying business trends.
  • The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook.
  • The resulting non-cash foreign exchange impact of such reclassification amounted to CHF 5.0 million or $5.7 million for the year ended December 31, 2023.

Sensus Healthcare to Participate in the 36th Annual Roth Conference

Retrieved on: 
Thursday, March 14, 2024
Dermatology, American Academy, Deal, Retail

BOCA RATON, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces management will participate in one-on-one or small group meetings with institutional investors at the 36th Annual Roth conference to be held March 17th – 19th in Dana Point, Calif. 

Key Points: 
  • Management will also discuss the reception it received at its booth at the American Academy of Dermatology Annual Meeting earlier this month, as described in its recently issued press release here .
  • Investor participation in the conference is by invitation only.
  • For more information or to request a meeting, please contact a Roth sales representative.
  • To submit a registration request, visit https://ibn.fm/Roth2024Registration .

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Research, Atopic dermatitis, PD, Inflammation, Patient, SAN, American Academy, Allergy, Investment, Antibody, Pharmacokinetics, SAD, AAAAI, Annual general meeting, Pharmaceutical industry

Research and development expenses were $53.8 million in the fourth quarter of 2023 compared to $35.4 million in the fourth quarter of 2022, an increase of $18.4 million.

Key Points: 
  • Research and development expenses were $53.8 million in the fourth quarter of 2023 compared to $35.4 million in the fourth quarter of 2022, an increase of $18.4 million.
  • Allakos reported a net loss of $62.6 million in the fourth quarter of 2023 compared to $43.0 million in the fourth quarter of 2022.
  • Net loss per basic and diluted share was $0.71 for the fourth quarter of 2023 compared to $0.50 in the fourth quarter of 2022.
  • Allakos ended the fourth quarter of 2023 with $170.8 million in cash, cash equivalents and investments resulting in a net decrease in cash, cash equivalents and investments of $23.1 million during the fourth quarter of 2023.

Astra Plastic Surgery adds double board-certified facial plastic surgeon to acclaimed roster

Retrieved on: 
Thursday, March 14, 2024
Emory University, Head, Patient, Breast, American Academy, Learning, Surgeon, Physician, Neck, Dentistry

ATLANTA, March 14, 2024 (GLOBE NEWSWIRE) -- Astra Plastic Surgery, an acclaimed North Georgia-based cosmetic and reconstructive surgery practice, is welcoming Dr. Paul Daraei, a double board-certified facial plastic surgeon, to its staff of seasoned physicians and surgeons at its Alpharetta and Cumming locations.

Key Points: 
  • ATLANTA, March 14, 2024 (GLOBE NEWSWIRE) -- Astra Plastic Surgery, an acclaimed North Georgia-based cosmetic and reconstructive surgery practice, is welcoming Dr. Paul Daraei, a double board-certified facial plastic surgeon, to its staff of seasoned physicians and surgeons at its Alpharetta and Cumming locations.
  • Learning from prestigious nationally and internationally renowned surgeons, he completed a rigorous head and neck surgical residency at Emory University, followed by a fellowship in cosmetic facial plastic surgery at Rousso Facial Plastic Surgery in Birmingham, Alabama.
  • “At Astra Plastic Surgery, we provide innovative and personalized care that meets our patients’ aesthetic goals and inspires confidence,” says Dr. Christopher Killingsworth, founder and managing partner of Astra Plastic Surgery.
  • Astra Plastic Surgery was established in 2012, recognizing the need for both cosmetic and reconstructive surgery in the North Atlanta area.

Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting

Retrieved on: 
Wednesday, March 13, 2024
Microglia, American Academy, American Academy of Neurology, ALSP, AAN, Poster

WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting taking place on April 13-18, 2024 in Denver, Colorado and virtually.

Key Points: 
  • WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting taking place on April 13-18, 2024 in Denver, Colorado and virtually.
  • Details of the oral presentation are as follows:
    Title: Interim Results on VGL101 From IGNITE: First Interventional Phase 2 Study in Patients with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
    Details of the poster presentations are as follows:
    Presented by: David S. Lynch, M.D., Ph.D., National Hospital for Neurology & Neurosurgery; University College London Institute of Neurology

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
Patient, G&A, BioCryst Pharmaceuticals, Eye, Drug delivery, Clinical trial, AAO, Extension, Webcast, Pharming, CPT, Safety, Disease, SPA, American Academy of Ophthalmology, Compass, Insurance, Diabetic retinopathy, Conference call, Aura, AMD, TKI, CLS, FDA, Administration, Conference, SCS, DME, American Academy, OASIS, Injection, Research and development, Axitinib, Pharmaceutical industry

ALPHARETTA, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • License Revenue: License and other revenue for the fourth quarter of 2023 was $6.3 million, compared to $0.3 million for the fourth quarter of 2022.
  • Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $6.3 million, compared to $5.0 million for the fourth quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2023 were $2.9 million, compared to $3.2 million for the fourth quarter of 2022.
  • Other Expense: Non-cash interest expense for the fourth quarter of 2023 was $2.3 million, compared to $2.0 million for the fourth quarter of 2022.

Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge

Retrieved on: 
Tuesday, March 12, 2024
Dermatology, Atopic dermatitis, Inflammation, JNJ, Research, American Academy, Cancer, FABP5, Skin, FABP, Pain, Epidermis, Oxidative stress, Pharmaceutical industry

SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge .

Key Points: 
  • SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge .
  • Artelo was awarded the opportunity to present preclinical dermatology research on ART26.12 in San Diego, California, on March 11, 2024, concurrent with the American Academy of Dermatology Annual Meeting.
  • "We are pleased to have been selected to present our ART26.12 program to the J&J immuno-dermatology leadership team," said Dr. Andrew Yates, Chief Scientific Officer of Artelo.
  • “Our drug discovery program is investigating several oral, small molecule, FABP5 inhibitors,” said Professor Saoirse O'Sullivan, Vice President Translational Science of Artelo.

Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy

Retrieved on: 
Thursday, April 4, 2024
Health, FDA, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Cell death, Medication, Survival, Wolfram syndrome, ALS, Partnership, Metabolism, Patient, AMX0035, Research, American Academy, OLE, Tauopathy, Health Canada, Biology, AAN, Clinical trial, Endoplasmic reticulum, Palsy, Workforce, Amylyx Pharmaceuticals, Division, Publication, Food, Vance DeGeneres, Pharmaceutical industry

Amylyx will continue to evaluate and share learnings from PHOENIX to help inform future ALS research.

Key Points: 
  • Amylyx will continue to evaluate and share learnings from PHOENIX to help inform future ALS research.
  • At this time, Amylyx intends to continue to collect available data on survival at the encouragement of ALS specialists.
  • “Our pipeline is supported by compelling clinical and preclinical science demonstrating the potential of AMX0035 and AMX0114 in neurodegenerative diseases.
  • “We are so thankful and grateful to our Amylyx team for their contributions and steadfast dedication,” said Cohen and Klee.